From:  Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study

Survival of patients with MSS according to PD-L1 CPS

Known PD-L1 CPSN, %PFSOS
Median, monthsHR, 95% CIMedian, monthsHR, 95% CI
< 1
≥ 1		4 (5.7)
67 (94.3)		1
3		0.32 (0.10–0.96)2
6		0.54 (0.19–1.53)
< 5
≥ 5		43 (60.5)
28 (39.4)		2
5		0.62 (0.30–1.43)6
15		0.53 (0.24–1.14)
< 10
≥ 10		47 (66.1)
24 (33.8)		2
5		0.44 (0.71–1.70)6
13		0.26 (0.25–1.45)
< 20
≥ 20		51 (71.8)
20 (28.1)		3
3		0.88 (0.32–2.59)6
13		0.77 (0.86–2.42)
Return to article view

MSS: microsatellite stable; PD-L1: programmed death-ligand 1; PFS: progression-free survival; OS: median overall survival; CPS: combined positive score; HR: hazard ratio